Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors (ICIs) are approved in urothelial carcinoma (UC).
To address the need for predictors of the efficacy of ICIs in metastatic urothelial carcinoma (mUC), randomized controlled trials of PD1/L1 inhibitors alone or in combination with chemotherapy in this patient population were systematically reviewed, and differences in ICI-associated survival outcomes according to available baseline variables were quantitatively assessed.
The quantitative analysis included 6524 patients with mUC. No visceral metastatic site (HR 0.67; 95% CI, 0.76-0.90) and high PDL-1 expression (HR 0.74; 95% CI, 0.640.87) were significantly associated with a reduced risk of death.
Treatment with an ICI-containing regimen was associated with a reduced risk of death in mUC patients, which was associated with PDL-1 expression and metastatic site. Further research is warranted.
Clinical genitourinary cancer. 2023 May 27 [Epub ahead of print]
Matteo Ferro, Felice Crocetto, Sabin Tataru, Biagio Barone, Pasquale Dolce, Giuseppe Lucarelli, Guru Sonpavde, Gennaro Musi, Alessandro Antonelli, Alessandro Veccia, Daniela Terracciano, Gian Maria Busetto, Francesco Del Giudice, Michele Marchioni, Luigi Schips, Francesco Porpiglia, Cristian Fiori, Giuseppe Carrieri, Francesco Lasorsa, Antonio Verde, Luca Scafuri, Carlo Buonerba, Giuseppe Di Lorenzo
Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: ., Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy., Department of Urology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Department of Public Health, Federico II University of Naples, Naples, Italy., Urology, Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy., Genitourinary Oncology and Phase I Section, AdventHealth Cancer Institute, Orlando, FL., Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy., Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy., Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy., Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy., Department of Urology, University of Chieti, Chieti, Italy., School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy., Oncology Unit, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Associazione O.R.A., Somma Vesuviana, Italy.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37419854